Clin2
NCT07769229Likely a fitNot yet recruiting

Bl-m09d1 for advanced gynecologic cancers

Gynecological MalignanciesSolid Tumors

This trial studies an experimental drug called BL-M09D1. It is given to people with certain gynecologic cancers and other solid tumors that have advanced and not responded to standard treatment. The goal is to see if the drug can help shrink or control the cancer.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
126 people
Ages
18 years to 75 years
Study type
Interventional

Who can take part

  • You are an adult 18 to 75 years old.
  • You have been diagnosed with a gynecologic cancer (like endometrial, cervical, ovarian, fallopian tube, or primary peritoneal) or another type of solid tumor.
  • Your cancer is locally advanced or metastatic, meaning it has spread beyond its original site, and standard treatment has either failed or you could not tolerate it.
  • You need to have at least one tumor that can be measured on imaging scans (like a CT scan).
  • You are physically able to care for yourself and do not have severe heart, lung, or kidney problems.
  • You can provide a sample of your tumor (from before or a fresh biopsy) for testing.

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT07780318Not yet recruiting· Phase 1/Phase 2
Study of BL-M08D for advanced digestive tract and other solid tumors

This trial tests a new drug called BL-M08D for people with advanced digestive tract tumors or other solid tumors that have spread. It aims to see if the drug can shrink tumors and improve survival, while monitoring safety.

Beijing, Beijing Municipality
NCT06131450Recruiting· Phase 1/Phase 2
Study of BL-M07D1 for HER2-positive gynecologic cancers

This trial tests a new drug called BL-M07D1 for women with HER2-positive or low-HER2 gynecologic cancers that have returned or spread. The drug is designed to target and kill cancer cells that make HER2, and may help when other treatments have stopped working.

Beijing, Beijing Municipality
NCT07788950Not yet recruiting· Phase 2
Study of BL-M08D1 for advanced head and neck cancer

This study tests an experimental drug called BL-M08D1 for people with head and neck cancer that has returned or spread. The drug is designed to target and destroy cancer cells, and the study will check if it is safe and how well it works.

Shanghai, Shanghai Municipality
NCT07279428Recruiting· Phase 1
Study of BL-M24D1 for advanced digestive and other solid tumors

This trial tests a new drug, BL-M24D1, in people with advanced or metastatic digestive tract cancers or other solid tumors that have not responded to standard treatments. The goal is to see if it is safe and effective.

Beijing, Beijing Municipality
NCT06954077Recruiting· Phase 1
BL-M09D1 for advanced gastrointestinal and other solid tumors

This trial tests a new drug, BL-M09D1, for people with advanced or metastatic gastrointestinal or other solid tumors that have stopped responding to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is.

Guangzhou, Guangdong
NCT07056556Recruiting· Phase 1
Study of BL-M09D1 for advanced lung and other solid tumors

This trial tests a new drug, BL-M09D1, in people with advanced non-small cell lung cancer or other solid tumors that have not responded to standard treatments. The goal is to see if the drug can help shrink or control the cancer.

Shanghai, Shanghai Municipality

Hear when a new Gynecological Malignancies trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.